Bridging Therapy for HCC

  • Shailesh Sable
  • Vinay Kumaran
Part of the GI Surgery Annual book series (GISA, volume 25)


Liver transplantation (LT) for hepatocellular carcinoma (HCC) has evolved from contraindication in the early 1990s to one of the common indications in today’s era. A lot of credit goes to the Milan criteria (1 lesion up to cm, 2–3 lesions up to 3 cm) for setting up this bench mark based on the seminal publication by Mazzaferro et al. nearly two decades ago [1]. LT provides a good 4-year survival rates (actuarial rate 74%) with low recurrence rates (recurrence-free survival rate of 83%) if performed for HCC within these criteria [1]. Liver transplant (LT) has a dual advantage as treatment; it is not only oncologically the best operation but it also cures the underlying cirrhosis. In view of longer wait times (due to shortage of organs) and high dropout rates (tumour progression/death), the practice of bridging (locoregional) therapy is becoming an essential part of HCC treatment. In this chapter we will discuss available evidence on the efficacy of bridging therapy for HCC. We will also discuss the current role of downstaging in the management of HCC. Towards the end we would like to highlight the role of bridging therapy in Indian scenario and also touch upon guidelines from Asian countries.


  1. 1.
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.CrossRefGoogle Scholar
  2. 2.
    Heimbach J, Kulik LM, Finn R, Sirlin CB, Abecassis M, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.CrossRefGoogle Scholar
  3. 3.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. Scholar
  4. 4.
    Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:11–22.CrossRefGoogle Scholar
  5. 5.
    Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the “wait and not ablate” approach until meeting T2 criteria for liver transplant listing. Liver Transpl. 2016;22:178–87.CrossRefGoogle Scholar
  6. 6.
    Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology. 2004;127(suppl 1):S261–7.CrossRefGoogle Scholar
  7. 7.
    Huo T-I, Huang Y-H, Su C-W, Lin H-C, Chiang J-H, Chiou Y-Y, et al. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. Clin Transpl. 2008;22:469–75.CrossRefGoogle Scholar
  8. 8.
    Llovet JM, Bruix J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology. 1998;27:1572–7.CrossRefGoogle Scholar
  9. 9.
    Bismuth H, Majno P, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 1999;19:311–22.CrossRefGoogle Scholar
  10. 10.
    Yao F, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl. 2003;9:684–92.CrossRefGoogle Scholar
  11. 11.
    Kulik L, Heimbach JK, Zaiem F, Almasri J, Prokop LJ, Wang Z, Murad MH, Mohammed K. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67(1):381–400.CrossRefGoogle Scholar
  12. 12.
    Andorno E, Bottino G, Morelli N, Casaccia M, Gelli M, Piredda D, et al. Preliminary results of liver transplantation for hepatocellular carcinoma among allocation organ policy strategies, neoadjuvant treatments, and intention-to-treat analysis. Transplant Proc. 2008;40:1972–3.CrossRefGoogle Scholar
  13. 13.
    DuBay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, et al. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford). 2011;13:24–32.CrossRefGoogle Scholar
  14. 14.
    Frangakis C, Geschwind JF, Kim D, Chen Y, Koteish A, Hong K, et al. Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list. Cardiovasc Intervent Radiol. 2011;34:1254–61.CrossRefGoogle Scholar
  15. 15.
    Heinzow HS, Meister T, Nass D, Kohler M, Spieker T, Wolters H, et al. Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma. Scand J Gastroenterol. 2011;46:201–10.CrossRefGoogle Scholar
  16. 16.
    Kim DY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, et al. Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization. World J Gastroenterol. 2006;12:6992–7.CrossRefGoogle Scholar
  17. 17.
    Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF, et al. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl. 2006;12:665–73.CrossRefGoogle Scholar
  18. 18.
    Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KVN, Quintini C, Hashimoto K, et al. Loco-regional therapy in patients with Milan criteria–compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis. HPB (Oxford). 2012;14:325–32.CrossRefGoogle Scholar
  19. 19.
    Park S-J, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, et al. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma. Clin Transpl. 2012;26:E359–64.CrossRefGoogle Scholar
  20. 20.
    Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant. 2008;8:958–76.CrossRefGoogle Scholar
  21. 21.
    Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–403.CrossRefGoogle Scholar
  22. 22.
    Patel SS, Arrington AK, McKenzie S, et al. Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States. Int J Hepatol. 2012;2012:253517.CrossRefGoogle Scholar
  23. 23.
    Yao FY, Hirose R, Laberge J, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 2005;11:1505–14.CrossRefGoogle Scholar
  24. 24.
    Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968–77.CrossRefGoogle Scholar
  25. 25.
    Heckman JT, deVera MB, Marsh JW, Fontes P, Amesur NB, Holloway SE, et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol. 2008;15:3169–77.CrossRefGoogle Scholar
  26. 26.
    Hołówko W, Wróblewski T, Wojtaszek M, Grąt M, Kobryń K, Ziarkiewicz-Wróblewska B, et al. Transarterial chemoembolization prior to liver transplantation in patients with hepatocellular carcinoma. Ann Transplant. 2015;20:764–8.CrossRefGoogle Scholar
  27. 27.
    Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent outcomes of liver transplantation following down staging of hepatocellular carcinoma to within Milan criteria—a multi-Center study. Clin Gastroenterol Hepatol. 2018;16(6):955–64.CrossRefGoogle Scholar
  28. 28.
    Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl. 2015;21:1142–52.CrossRefGoogle Scholar
  29. 29.
    Rassiwala J. Are there upper limits in tumor burden for successful down-staging of hepatocellular carcinoma to liver transplant? Analysis of the “All-comers” down-staging protocol AASLD liver learning (abstract no 137). Hepatology 14 Nov 2016:155411.Google Scholar
  30. 30.
    Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006;12:1260–7.CrossRefGoogle Scholar
  31. 31.
    Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadimann S, Ladurner R, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007;13:272–9.CrossRefGoogle Scholar
  32. 32.
    Martin AP, Goldstein RM, Dempster J, et al. Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation—a clinical and histological examination. Clin Transpl. 2006;20:695–705.CrossRefGoogle Scholar
  33. 33.
    Pompili M, Mirante VG, Rondinara G, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explants analysis and of safety for tumor recurrence. Liver Transpl. 2005;11:1117–26.CrossRefGoogle Scholar
  34. 34.
    Mohan Foundation. Cadaver organ transplantation in India. [Homepage on the Internet, cited 2015 Jun 15]. 2015. Available from:
  35. 35.
    Soin AS. Our journey of liver transplantation at Sir Ganga Ram and Medanta Hospitals: a rewarding decade of trials and tribulations. In: Nundy S, editor. Liver transplantation in India. Gurgaon: Elsevier; 2011.Google Scholar
  36. 36.
    Kakodkar R, Soin AS. Liver transplantation for HCC: a review. Indian J Surg. 2012;74:100–17.CrossRefGoogle Scholar
  37. 37.
    Narasimhan G, Kota V, Rela M. Liver transplantation in India. Liver Transpl. 2016;22:1019–24.CrossRefGoogle Scholar
  38. 38.
    Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, et al. The Indian National Association for Study of the Liver (INASL) consensus on prevention, diagnosis and management of hepatocellular carcinoma in India: the puri recommendations. J Clin Exp Hepatol. 2014;4:S3–S26.CrossRefGoogle Scholar
  39. 39.
    Korean Liver Cancer Study Group, National Cancer Center, Korea. 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut Liver. 2015;9:267–317.Google Scholar
  40. 40.
    Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Local Ablation Group, TACE/TARE/HAI Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381–403.CrossRefGoogle Scholar
  41. 41.
    Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC guidelines). Hepatol Res. 2015;45:123–7.CrossRefGoogle Scholar
  42. 42.
    Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–70.CrossRefGoogle Scholar
  43. 43.
    Xie D-Y, Ren Z-G, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. HepatoBiliary Surg Nutr. 2017;6(6):387–396s.CrossRefGoogle Scholar
  44. 44.
    Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl. 2010;16:262–78.CrossRefGoogle Scholar
  45. 45.
    Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G, et al. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl. 2011;17:1344–54.CrossRefGoogle Scholar
  46. 46.
    Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013;19:1343–53.CrossRefGoogle Scholar
  47. 47.
    Sheth RA, Patel MS, Koottappillil B, Shah JA, Oklu R, Mueller P, et al. Role of locoregional therapy and predictors for dropout in patients with hepatocellular carcinoma listed for liver transplantation. J Vasc Interv Radiol. 2015;26:1761–8; quiz 1768.CrossRefGoogle Scholar
  48. 48.
    Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol. 2012;57:1258–67.CrossRefGoogle Scholar
  49. 49.
    Agopian VG, Harlander-Locke MP, Ruiz RM, Klintmalm GB, Senguttuvan S, Florman SS, et al. Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation: analysis of 3601 patients from the US Multicenter HCC transplant consortium. Ann Surg. 2017;266:525–35.CrossRefGoogle Scholar
  50. 50.
    Chan KM, Yu MC, Chou HS, Wu TJ, Lee CF, Lee WC. Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation. Ann Surg Oncol. 2011;18:2638–46.CrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Gastroenterology 2019

Authors and Affiliations

  • Shailesh Sable
    • 1
  • Vinay Kumaran
    • 2
  1. 1.Liver Transplant and HPB SurgeryKokilaben Dhirubhai Ambani HospitalMumbaiIndia
  2. 2.Liver Transplant and HPB SurgeryShalby HospitalAhmedabadIndia

Personalised recommendations